Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)

October 11, 2024 6:36 AM EDT Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on Sutro Biopharma (NASDAQ: STRO).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login